Abivax SA is set to present nine scientific abstracts on obefazimod, its lead drug candidate for treating moderately to severely active ulcerative colitis (UC), at the upcoming 2026 Digestive Disease Week (DDW) in Chicago. These presentations will detail findings from the Phase 3 ABTECT program, focusing on efficacy, safety, and patient-reported outcomes, alongside preclinical data demonstrating anti-fibrotic activity in two models of fibrosis. Dr. Fabio Cataldi, Abivax’s Chief Medical Officer, emphasized that the data showcases significant improvements in histologic and endoscopic outcomes, as well as patient-reported enhancements in fatigue and quality of life.

The significance of these findings lies in their potential to transform treatment paradigms for UC. The comprehensive dataset reinforces obefazimod’s role as a promising therapeutic option, addressing critical aspects of patient care that extend beyond mere symptom management. With a focus on both clinical efficacy and patient-reported outcomes, the data suggests that obefazimod could fundamentally improve the quality of life for patients suffering from this chronic condition. This aligns with the growing emphasis on patient-centered approaches in therapeutic development.

The implications of this research extend to the broader field of inflammatory bowel disease (IBD) treatment. As Abivax builds a robust dataset, the findings may accelerate the timeline for drug development and regulatory approval processes, potentially leading to new standards of care in UC management. This positions obefazimod not only as a treatment option but also as a catalyst for innovation in the IBD landscape, prompting further exploration of similar therapeutic strategies targeting the immune response in chronic inflammatory diseases.

Source: globenewswire.com